Last reviewed · How we verify
NCT05156606: T&T
Testosterone & Tamoxifen Trial
NA trial testing AndroGel in Male Breast Cancer in 5 participants. Terminated before completion.
31 July 2024
Quick facts
| Lead sponsor | University Medical Center Groningen |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 10 November 2022 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- AndroGel — full drug profile →
Conditions studied
- Male Breast Cancer — all drugs for Male Breast Cancer →
Sponsor
University Medical Center Groningen
Who can join
18 and older, male only, with Male Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a concise single arm, feasibility study, which will be executed in the University Medical Center Groningen, The Netherlands. Male patients with metastatic BC (n=6) are eligible for this study after at least 1 line of conventional endocrine therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Revisiting Androgen Receptor Signaling in Breast Cancer.
Dai C, Ellisen LW. · · 2023 · cited 26× · PMID 36972361 · DOI 10.1093/oncolo/oyad049 -
Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.
Tien AH, Sadar MD. · · 2024 · cited 11× · PMID 38339092 · DOI 10.3390/ijms25031817
Verify or expand the search:
- PubMed search for NCT05156606
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AndroGel
Trials testing the same drug.
- NCT04492553 — Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality · Phase 2 · completed
- NCT03198728 — Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men · Phase 3 · completed
Other recruiting trials for Male Breast Cancer
Currently open trials in the same condition.
- NCT05501704 — ETHAN - ET for Male BC · Phase 2 · recruiting
Other University Medical Center Groningen trials
Trials by the same sponsor.
- NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
- NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
- NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
- NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
- NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05156606 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156606.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing